title: The therapeutic potential of nanoscale sphingolipid technologies.
abstract: Nanotechnologies, while small in size, widen the scope of drug delivery options for compounds with problematic pharmacokinetics, such as bioactive sphingolipids. We describe the development of historical sphingolipid nanotechnologies, such as nanoliposomes, and project future uses for a broad repertoire of nanoscale sphingolipid therapy formulations. In particular, we describe sphingo-nanotherapies for treatment of cancer, inflammatory disease, and cardiovascular disease. We conclude with a discussion of the challenges associated with regulatory approval, scale-up, and development of these nanotechnology therapies for clinical applications.
authors.affiliation: Department of Pharmacology, R130, Penn State University College of Medicine, Hershey, PA 17033, USA.
authors.forename: Jody L
authors.initials: JL
authors.lastname: Hankins
authors.forename: Ushma A
authors.initials: UA
authors.lastname: Doshi
authors.forename: Jeremy K
authors.initials: JK
authors.lastname: Haakenson
authors.forename: Megan M
authors.initials: MM
authors.lastname: Young
authors.forename: Brian M
authors.initials: BM
authors.lastname: Barth
authors.forename: Mark
authors.initials: M
authors.lastname: Kester
mesh_terms: D002318:Cardiovascular Diseases / Q000188:drug therapy; D006801:Humans; D007109:Immunity / Q000187:drug effects; D008081:Liposomes; D036103:Nanotechnology; D009369:Neoplasms / Q000188:drug therapy; D013107:Sphingolipids / Q000008:administration & dosage*
chemical_list: D008081:Liposomes; D013107:Sphingolipids